FibroBiologics Files 8-K on Corporate Actions
Ticker: FBLG · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1958777
Sentiment: neutral
Topics: corporate-governance, financial-reporting, 8-k
TL;DR
FibroBiologics filed an 8-K detailing corporate changes and financial updates.
AI Summary
FibroBiologics, Inc. filed an 8-K on August 27, 2024, reporting on several key corporate actions. These include amendments to its articles of incorporation or bylaws, the submission of matters to a vote of security holders, and the filing of financial statements and exhibits. The company is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing provides updates on significant corporate governance and financial reporting events for FibroBiologics, Inc., which can impact investor understanding of the company's structure and performance.
Risk Assessment
Risk Level: low — This filing is primarily procedural, reporting on corporate actions and financial statements without immediate significant financial or operational news.
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal business address
FAQ
What specific amendments were made to FibroBiologics' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote, but the nature of these matters is not detailed in the provided text.
What financial statements and exhibits are included in this filing?
The filing confirms the submission of financial statements and exhibits, but their specific content is not described in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 27, 2024.
What is FibroBiologics, Inc.'s Standard Industrial Classification (SIC) code?
FibroBiologics, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2024-08-28 16:01:17
Key Financial Figures
- $0.00001 — ichregistered Common stock, par value $0.00001 per share FBLG Nasdaq Global Marke
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex3-1.htm (EX-3.1) — 65KB
- 0001493152-24-034182.txt ( ) — 310KB
- fblg-20240827.xsd (EX-101.SCH) — 3KB
- fblg-20240827_lab.xml (EX-101.LAB) — 33KB
- fblg-20240827_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 28, 2024 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer